Medulloblastoma is the most common malignant brain tumor in children. Treatment intensification has led to improved survival rates but with a heavy burden of morbidity. The key clinical strategy is to personalize treatment through risk stratification in a manner which ensures the maximum chance of long term survival whilst minimizing morbidity. The identification of novel biomarkers of prognosis is an important part of this strategy and much progress has been made in defining molecular genetic subgroups. However, less progress has been made in identifying downstream molecular markers and this study presents a novel biomarker of poor prognosis; intra-tumoral gluatamate. This is of particular clinical relevance since it can be detected non-invasively allowing the result to be available prior to surgery and at follow-up if there is residual tumor. Incorporation in multi-centre clinical trials is required to allow its role in treatment decision making to be defined.
Introduction
Brain tumors present the highest cancer-related mortality rate in children, and medulloblastoma is the most common malignant brain tumor occurring in childhood (1) . Whilst survival rates have improved, the prognosis for this disease remains relatively poor, and survivors often suffer a range of deficits due the limited specificity of available treatment options (2, 3). Current risk stratification for treatment of medulloblastoma primarily depends on: disease spread; the extent of residual disease following resection; patient age; and histologic sub-type (4).
However considerable variation in survival is still found within these criteria (5), Non-invasive molecular investigations offer great potential for improving disease management and stratification in medulloblastoma. Unlike conventional molecular markers that require biopsy tissue, non-invasive methods could be used to safely monitor patients at regular intervals, providing dynamic information on disease progression. 1 H magnetic resonance spectroscopy (MRS) is a widely available technique, providing non-invasive measurement of tissue metabolite concentrations.
Previous studies of pediatric brain tumors have found that MRS can detect a number of metabolites, which are predictive of survival across a range of tumor types (9, 10).
However, prognostic biomarkers that are tailored to the tumor type have greater clinical value.
In this study we evaluate the potential of pre-treatment MRS to provide non-invasive predictive molecular biomarkers in a cohort of pediatric medulloblastoma. A simple protocol of single voxel MRS and fully automated spectral analysis was chosen to reduce barriers to widespread adoption of the method.
Materials and Methods
All patients with a confirmed diagnosis of medulloblastoma undergoing MR imaging at Birmingham Children's Hospital were eligible to be enrolled on this study. Patients were enrolled on a consecutive basis without additional selection. The accrual period was between September 2003 and September 2011 and patients were followed up until July 2012. The accrual period was chosen to ensure at least 30 patients were included in the study, since an initial power calculation (two-sample comparison of proportions) showed that 15 patients in two equally sized groups with survival probabilities of 25% and 75% would have a power of 82% at a 5% significance level using a two-sided test. Survival time was defined as the period between the date of (11)). The clinical and radiological features were also reviewed by the multidisciplinary team. Approval was obtained from the research ethics committee and informed consent given by parents/guardians. Investigators were not blinded to patient information, however since the MRS methodology chosen was fullyautomated, and therefore user independent, interpretation bias was eliminated.
Since the study spanned a large time period, a number of different treatment protocols were used and are given in supplementary material. The treatment protocols followed national and international clinical trials or guidelines where available and local guidelines based on previous clinical trials where these were not available. The general principles were that a maximal surgical resection of the primary tumor was followed by adjuvant treatment. Children under 3 years of age were treated with intensive chemotherapy regimes and often focal radiotherapy. Older children received craniospinal radiotherapy and chemotherapy, with high-risk patients receiving higher doses of radiotherapy than those with standard risk. Standard risk patients were defined as being older than 3 years of age, M0 stage, no adverse histology and a complete or near complete resection of the primary tumor. Anaplastic or large cell medulloblastoma were both considered as adverse histological subtypes. Near complete resection was defined a residual tumor of less than 1.5cm 2 , measured from the imaging slice displaying the largest cross-section of tumor.
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on were not considered as individual measurements, since it is unlikely that these signals can be resolved at 1.5T given the high degree of overlap and low level of TNAA in this tumor group.
Each spectrum and its associated voxel placement were reviewed. Data were rejected if any of the following conditions were met: the voxel was placed closer than 4mm to lipid containing structures, greater than 5% of the voxel was estimated to contain noninvolved brain, the baseline was unstable, obvious artefacts were present, the signalto-noise ratio (SNR) was less than 4 or the overall metabolite linewidth exceeded 0.15ppm.
To reduce the risk of type I errors in the analysis, the cohort was split into two groups to allow a subsequent validation step: 1) patients diagnosed before January 2007 and 2) patients diagnosed after January 2007. These two groups are referred to as the initial and validation cohorts respectively. An exploratory statistical analysis was carried out on the initial cohort to establish potential non-invasive metabolite biomarkers of survival for medulloblastoma. Since MRS can provide a number of potential biomarkers, a more stringent significance value of p<0.01 was chosen to reduce errors associated with multiple comparisons. Kaplan-Meier survival analysis was performed on the initial cohort for each metabolite by dividing the cohort into two groups; cases with metabolite concentrations above and below a cut off value. The optimal cut off value was found for each metabolite by performing a chi-squared significance test over a range of values. Values that resulted in fewer than 5 cases in either group were not considered due to statistical instabilities. Hazard ratios were calculated at the determined cut-off using Cox-Regression. The metabolites associated with survival in the initial cohort were then tested pseudo-prospectively on the validation cohort by performing a Kaplan-Meir survival analysis using the same cut-off values. the in vivo data since water reference data for absolute quantitation was not available for the ex-vivo data. The association between ex-vivo and in-vivo data was assessed graphically and a Pearson product-moment correlation coefficient was calculated.
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Results
A total of 35 medulloblastoma patients were eligible for the study and 17 had died by the end of the study period. In one case, the in vivo MRS failed QC due to baseline distortion, making quantitation unreliable, and was excluded from further analysis.
The baseline was poor for this particular case due to insufficient water suppression leaving residual signal; an example of this spectrum is given alongside a normal appearing baseline in supplementary Optimal metabolite cutoff values and their respective hazard ratios and significances for the initial cohort (N=15) are given in Table 1 . Three of the fourteen metabolites tested were found to be predictors of survival (p<0.01); creatine, glutamate and glycine. A subsequent survival analysis of creatine, glutamate and glycine on the validation cohort, using the same cutoff values determined from the initial cohort, found only glutamate to be significant (p=0.0096). Glutamate was found to have a hazard ratio of 8.0 with lower and upper confidence intervals of 2.2 and 29.0 respectively (likelihood ratio test p=0.0003) for the full cohort using a cutoff value of 2.77mM. Figure 1 shows Kaplan-Meier survival plots for glutamate for the A) initial cohort; B) validation cohort and C) full cohort. 
The 35 cases included in this study were found to belong to the following histologic subtypes: classic medulloblastoma (N=31); desmoplastic/nodular medulloblastoma (N=2) and large-cell medulloblastoma (N=2). A summary of patient characteristics and common clinical prognostic markers are given in Table 2 . The full cohort (excluding one case due to failed MRS QC) consisted of a relatively high proportion of boys to girls (2.4) with the population level expected to be between 1.5 and 2.0 (1) but no difference was found between the survival of boys and girls (p=0.5, chisquared significance test). Age at diagnosis was found to predict survival in this cohort with patients under the age of five doing significantly worse than those who were older (p<0.002, chi-squared significance test), a finding consistent with previous studies (15) . Both cases with large-cell medulloblastoma had high levels of glutamate. No difference in survival was found between cases with non-metastatic (M0) and metastatic (M+) disease for children of all ages (p=0.5, chi-squared significance test).
In addition, no association was found between glutamate levels and patient age (p=0.9, t-test); metastatic stage (p=0.5, Fisher's Exact Test) or sub-total resection of primary tumor (p=0.6, Fisher's Exact Test). Glutamate was also found to be a 
predictor (p<0.001, chi-squared significance test) of survival in the high-risk patients alone (N=18). Three of the cases treated on the standard risk protocol that had died within the study period were classified as having a high level of glutamate.
A scatter plot of glutamate values for all cases is given in Figure 2 , with the optimal cutoff value found from the initial cohort represented as a horizontal line. No significant outliers are seen.
In addition to the sophisticated MRS analysis using TARQUIN (14), a simpler analysis was performed using spectral integration to help confirm the assignment of glutamate in the MRS. An integration of the main glutamate spectral region (between 2.1 and 2.5ppm) was found to be predictive of survival in the full cohort (p<0.05).
Average spectra are shown in Figure 3 for cases with high (>2.77mM) and low (≤2.77mM) levels of glutamate. 
Discussion
This study has shown that the concentration of glutamate, detected using in-vivo MRS, predicts the survival of children with medulloblastoma. The lack of a strong association between glutamate levels and other known clinical and radiological risk factors implies that this could be a new prognostic risk factor. Three patients with standard risk disease and high levels of glutamate died within the study period and may have benefited from more intensive treatment, in addition, high glutamate was predictive of poor survival in the sub-group of high risk cases. Glutamate could therefore provide improved treatment stratification for both high risk and standard risk medulloblastoma. In this study, the limited information available from tumor genetic testing failed to show an association with poor outcome but it is possible that glutamate mirrors molecular genetic subgroups of poor prognosis and this needs further exploration. Glutamate was found to be significantly associated with survival in both the initial and validation cohorts despite an overall improvement in survival in the later cohort.
Comparing the patient characteristics in the initial cohort and the validation cohort, Table 2 indicates that they are similar except for fewer patients with M0 disease in the initial cohort. In terms of treatment, children in the initial cohort were less likely to have a complete resection of the primary but more likely to have focal radiotherapy or less than 30Gy craniospinal radiotherapy. The trends in treatment are as expected with the emergence of protocols using lower doses of craniospinal radiotherapy for those with standard risk disease.
Since all the patients were not treated in a uniform manner, treatment could be a potential confounder in the analysis. However, the finding that glutamate is a strong marker of prognosis in two cohorts with consecutive time spans, and therefore treated with different protocols, implies that treatment effects do not account for the finding that high glutamate is associated with poor prognosis. Further studies of specific treatment groups should be undertaken to identify the patient groups for which glutamate level is most relevant. Indeed, the relatively high percentage of cases with metastatic disease and the high number of young children with M0 classic medulloblastoma make this a cohort with relatively poor prognosis -for which the discovery of novel biomarkers of prognosis is all the more important. 
overlapping with macromolecule resonances around 2ppm. Despite this, Figure 4 demonstrates a good correlation between in-vivo and ex-vivo MRS indicating that the combination of a short-echo time MRS protocol and automated spectral fitting (14) provides reliable quantitation. Furthermore, MRS quantitation accuracy in medulloblastoma is also aided by high quality data, due to minimal magnetic susceptibility issues in the cerebellum, and dense cellularity giving high signal-tonoise. A separate analysis of the available ex-vivo MRS showed that glutamate/totalcholine ratio is predictive of survival. Total-choline will contribute to this finding if low values are associated with poor survival, although this was not found in-vivo. The main limitations of this study were the relatively small numbers (N=35) available and multiple variables considered in the analysis, mitigated to a degree by setting a significance level of p<0.01 and performing validation on a test dataset. Whilst this study should be considered as exploratory in nature, multi-center validation is warranted.
In conclusion, the identification of glutamate as a non-invasive prognostic marker of survival in pediatric medulloblastoma offers the potential for improved disease management and highlights related molecular targets for therapy. Future work includes a comparison with established molecular subgroups and multi-center evaluation of this biomarker.
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